Skip to main content
Premium Trial:

Request an Annual Quote

Mayo Clinic, U of Minnesota Open $22M Genomics Facility

NEW YORK (GenomeWeb News) - A Minnesota research collaboration headed by the Mayo Clinic has established a new genomics and bioinformatics facility in Rochester, Minn., the Minnesota Partnership for Biotechnology and Medical Genomics said Friday.
 
The facility, a three-story addition to a space in downtown Rochester, will house genomics research equipment, a bioinformatics lab, and conference rooms to support the partnership’s research initiatives.
 
The state legislature provided $21.7 million in backing for the facility, which is the product of a partnership involving the Mayo Clinic, the University of Minnesota, and the State of Minnesota.
 
The Minnesota Partnership said ongoing research includes "anti-cancer drug development, heart disease, pancreatic cancer, neuromuscular diseases, tuberculosis, auto-immune diseases, transplant rejection, drug addiction and tuberculosis."
 
Describing itself as "a unique collaborative venture," the Minnesota Partnership aims to head the region’s biotech and genomics sector.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.